10X Genomics Inc (TXG) - Net Assets
Based on the latest financial reports, 10X Genomics Inc (TXG) has net assets worth $786.33 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.03 Billion) and total liabilities ($241.03 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 10X Genomics Inc asset portfolio for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $786.33 Million |
| % of Total Assets | 76.54% |
| Annual Growth Rate | N/A |
| 5-Year Change | -3.92% |
| 10-Year Change | N/A |
| Growth Volatility | 31.3 |
10X Genomics Inc - Net Assets Trend (2017–2024)
This chart illustrates how 10X Genomics Inc's net assets have evolved over time, based on quarterly financial data. Check 10X Genomics Inc tangible book value ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for 10X Genomics Inc (2017–2024)
The table below shows the annual net assets of 10X Genomics Inc from 2017 to 2024. For live valuation and market cap data, see 10X Genomics Inc (TXG) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $710.13 Million | -4.17% |
| 2023-12-31 | $741.04 Million | -8.03% |
| 2022-12-31 | $805.74 Million | -1.45% |
| 2021-12-31 | $817.57 Million | +10.62% |
| 2020-12-31 | $739.07 Million | +75.93% |
| 2019-12-31 | $420.08 Million | +290.96% |
| 2018-12-31 | $-219.99 Million | -95.53% |
| 2017-12-31 | $-112.51 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to 10X Genomics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 134841600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.00% |
| Other Comprehensive Income | $-493.00K | -0.07% |
| Other Components | $2.18 Billion | 306.66% |
| Total Equity | $710.13 Million | 100.00% |
10X Genomics Inc Competitors by Market Cap
The table below lists competitors of 10X Genomics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ganfeng Lithium Co. Ltd
F:39EA
|
$2.35 Billion |
|
Sinocelltech Group Ltd
SHG:688520
|
$2.35 Billion |
|
Wafer Works
TWO:6182
|
$2.35 Billion |
|
Huaming Power Equipment Co Ltd
SHE:002270
|
$2.35 Billion |
|
The Ramco Cements Limited
NSE:RAMCOCEM
|
$2.35 Billion |
|
Zhongshan Public Utilities Group Co Ltd
SHE:000685
|
$2.35 Billion |
|
SIMMTECH Co. Ltd
KQ:222800
|
$2.34 Billion |
|
Qinhuangdao Port Co Ltd
SHG:601326
|
$2.34 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 10X Genomics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 741,043,000 to 710,134,000, a change of -30,909,000 (-4.2%).
- Net loss of 182,627,000 reduced equity.
- Other comprehensive income decreased equity by 64,000.
- Other factors increased equity by 151,782,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-182.63 Million | -25.72% |
| Other Comprehensive Income | $-64.00K | -0.01% |
| Other Changes | $151.78 Million | +21.37% |
| Total Change | $- | -4.17% |
Book Value vs Market Value Analysis
This analysis compares 10X Genomics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.01x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-9.71 | $47.20 | x |
| 2018-12-31 | $-16.43 | $47.20 | x |
| 2019-12-31 | $5.37 | $47.20 | x |
| 2020-12-31 | $7.31 | $47.20 | x |
| 2021-12-31 | $7.41 | $47.20 | x |
| 2022-12-31 | $7.08 | $47.20 | x |
| 2023-12-31 | $6.32 | $47.20 | x |
| 2024-12-31 | $5.90 | $47.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 10X Genomics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -25.72%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -29.90%
- • Asset Turnover: 0.66x
- • Equity Multiplier: 1.29x
- Recent ROE (-25.72%) is below the historical average (-21.09%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | -26.39% | 0.94x | 0.00x | $-7.51 Million |
| 2018 | 0.00% | -76.88% | 1.18x | 0.00x | $-90.49 Million |
| 2019 | -7.44% | -12.71% | 0.41x | 1.44x | $-73.26 Million |
| 2020 | -73.43% | -181.61% | 0.32x | 1.26x | $-616.64 Million |
| 2021 | -7.12% | -11.87% | 0.48x | 1.25x | $-139.98 Million |
| 2022 | -20.60% | -32.15% | 0.50x | 1.28x | $-246.57 Million |
| 2023 | -34.42% | -41.23% | 0.64x | 1.30x | $-329.20 Million |
| 2024 | -25.72% | -29.90% | 0.66x | 1.29x | $-253.64 Million |
Industry Comparison
This section compares 10X Genomics Inc's net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $521,029,732
- Average return on equity (ROE) among peers: -26.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 10X Genomics Inc (TXG) | $786.33 Million | 0.00% | 0.31x | $2.35 Billion |
| Aclarion Inc (ACON) | $-728.00K | 0.00% | 0.00x | $1.48 Million |
| American Well Corp (AMWL) | $316.24 Million | -65.82% | 0.38x | $133.17 Million |
| Heartbeam Inc (BEAT) | $249.70 Million | -6.39% | 1.10x | $32.87 Million |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG) | $2.59 Million | -206.61% | 0.07x | $6.51 Million |
| BrightSpring Health Services, Inc. Common Stock (BTSG) | $1.65 Billion | -1.09% | 2.59x | $10.63 Billion |
| Carlsmed, Inc. Common Stock (CARL) | $-46.13 Million | 0.00% | 0.00x | $312.63 Million |
| CareCloud, Inc. (CCLD) | $406.08K | 28.81% | 7.58x | $94.76 Million |
| Certara Inc (CERT) | $822.13 Million | -6.01% | 0.54x | $1.09 Billion |
| CareMax Inc (CMAX) | $505.37 Million | -1.32% | 0.29x | $381.50 |
| Claritev Corporation (CTEV) | $1.71 Billion | -5.37% | 3.08x | $460.29 Million |
About 10X Genomics Inc
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and … Read more